nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—ORM1—saliva—attention deficit hyperactivity disorder	0.0473	0.0557	CbGeAlD
Erlotinib—ULK3—forebrain—attention deficit hyperactivity disorder	0.0201	0.0236	CbGeAlD
Erlotinib—FLT3—cardiovascular system—attention deficit hyperactivity disorder	0.0197	0.0232	CbGeAlD
Erlotinib—AURKC—nervous system—attention deficit hyperactivity disorder	0.0173	0.0204	CbGeAlD
Erlotinib—AURKC—central nervous system—attention deficit hyperactivity disorder	0.0167	0.0196	CbGeAlD
Erlotinib—JAK3—nervous system—attention deficit hyperactivity disorder	0.016	0.0189	CbGeAlD
Erlotinib—EPHA6—nervous system—attention deficit hyperactivity disorder	0.016	0.0189	CbGeAlD
Erlotinib—MKNK1—cardiovascular system—attention deficit hyperactivity disorder	0.016	0.0188	CbGeAlD
Erlotinib—HIPK4—brain—attention deficit hyperactivity disorder	0.0155	0.0182	CbGeAlD
Erlotinib—JAK3—central nervous system—attention deficit hyperactivity disorder	0.0154	0.0181	CbGeAlD
Erlotinib—EPHA6—central nervous system—attention deficit hyperactivity disorder	0.0154	0.0181	CbGeAlD
Erlotinib—LTK—brain—attention deficit hyperactivity disorder	0.0153	0.018	CbGeAlD
Erlotinib—JAK3—cerebellum—attention deficit hyperactivity disorder	0.0151	0.0177	CbGeAlD
Erlotinib—MAP3K19—nervous system—attention deficit hyperactivity disorder	0.0146	0.0171	CbGeAlD
Erlotinib—MAP3K19—central nervous system—attention deficit hyperactivity disorder	0.014	0.0165	CbGeAlD
Erlotinib—PIP4K2C—midbrain—attention deficit hyperactivity disorder	0.0139	0.0163	CbGeAlD
Erlotinib—TNK1—cerebellum—attention deficit hyperactivity disorder	0.0138	0.0163	CbGeAlD
Erlotinib—ULK3—midbrain—attention deficit hyperactivity disorder	0.0133	0.0156	CbGeAlD
Erlotinib—AURKC—brain—attention deficit hyperactivity disorder	0.0132	0.0156	CbGeAlD
Erlotinib—STK10—cardiovascular system—attention deficit hyperactivity disorder	0.0132	0.0155	CbGeAlD
Erlotinib—MKNK1—midbrain—attention deficit hyperactivity disorder	0.0125	0.0147	CbGeAlD
Erlotinib—EPHA6—brain—attention deficit hyperactivity disorder	0.0122	0.0144	CbGeAlD
Erlotinib—JAK3—brain—attention deficit hyperactivity disorder	0.0122	0.0144	CbGeAlD
Erlotinib—FLT3—cerebellum—attention deficit hyperactivity disorder	0.0119	0.014	CbGeAlD
Erlotinib—SLK—midbrain—attention deficit hyperactivity disorder	0.0118	0.0139	CbGeAlD
Erlotinib—MAP2K5—cardiovascular system—attention deficit hyperactivity disorder	0.0118	0.0138	CbGeAlD
Erlotinib—PIP4K2C—nervous system—attention deficit hyperactivity disorder	0.0114	0.0134	CbGeAlD
Erlotinib—ABL2—cerebellum—attention deficit hyperactivity disorder	0.0114	0.0134	CbGeAlD
Erlotinib—TNK1—brain—attention deficit hyperactivity disorder	0.0112	0.0132	CbGeAlD
Erlotinib—MAP3K19—brain—attention deficit hyperactivity disorder	0.0111	0.0131	CbGeAlD
Erlotinib—EGFR—cerebellum—attention deficit hyperactivity disorder	0.0111	0.013	CbGeAlD
Erlotinib—PIP4K2C—central nervous system—attention deficit hyperactivity disorder	0.011	0.0129	CbGeAlD
Erlotinib—ULK3—nervous system—attention deficit hyperactivity disorder	0.0109	0.0128	CbGeAlD
Erlotinib—SLCO2B1—forebrain—attention deficit hyperactivity disorder	0.0108	0.0127	CbGeAlD
Erlotinib—PIP4K2C—cerebellum—attention deficit hyperactivity disorder	0.0107	0.0126	CbGeAlD
Erlotinib—ULK3—central nervous system—attention deficit hyperactivity disorder	0.0105	0.0123	CbGeAlD
Erlotinib—MKNK1—nervous system—attention deficit hyperactivity disorder	0.0103	0.0121	CbGeAlD
Erlotinib—ULK3—cerebellum—attention deficit hyperactivity disorder	0.0103	0.0121	CbGeAlD
Erlotinib—MKNK1—central nervous system—attention deficit hyperactivity disorder	0.00988	0.0116	CbGeAlD
Erlotinib—MKNK1—cerebellum—attention deficit hyperactivity disorder	0.00965	0.0114	CbGeAlD
Erlotinib—ABL2—brain—attention deficit hyperactivity disorder	0.00922	0.0109	CbGeAlD
Erlotinib—MAP2K5—midbrain—attention deficit hyperactivity disorder	0.00918	0.0108	CbGeAlD
Erlotinib—SLK—cerebellum—attention deficit hyperactivity disorder	0.00914	0.0108	CbGeAlD
Erlotinib—ABL1—cardiovascular system—attention deficit hyperactivity disorder	0.00907	0.0107	CbGeAlD
Erlotinib—EGFR—brain—attention deficit hyperactivity disorder	0.009	0.0106	CbGeAlD
Erlotinib—PIP4K2C—brain—attention deficit hyperactivity disorder	0.00873	0.0103	CbGeAlD
Erlotinib—STK10—nervous system—attention deficit hyperactivity disorder	0.00845	0.00994	CbGeAlD
Erlotinib—ULK3—brain—attention deficit hyperactivity disorder	0.00833	0.0098	CbGeAlD
Erlotinib—STK10—central nervous system—attention deficit hyperactivity disorder	0.00813	0.00957	CbGeAlD
Erlotinib—STK10—cerebellum—attention deficit hyperactivity disorder	0.00795	0.00935	CbGeAlD
Erlotinib—MKNK1—brain—attention deficit hyperactivity disorder	0.00784	0.00923	CbGeAlD
Erlotinib—CYP1B1—cardiovascular system—attention deficit hyperactivity disorder	0.00768	0.00903	CbGeAlD
Erlotinib—MAP2K5—nervous system—attention deficit hyperactivity disorder	0.00754	0.00888	CbGeAlD
Erlotinib—SLK—brain—attention deficit hyperactivity disorder	0.00743	0.00874	CbGeAlD
Erlotinib—MAP2K5—central nervous system—attention deficit hyperactivity disorder	0.00726	0.00855	CbGeAlD
Erlotinib—MAP2K5—cerebellum—attention deficit hyperactivity disorder	0.0071	0.00835	CbGeAlD
Erlotinib—ABL1—midbrain—attention deficit hyperactivity disorder	0.00708	0.00833	CbGeAlD
Erlotinib—STK10—brain—attention deficit hyperactivity disorder	0.00646	0.0076	CbGeAlD
Erlotinib—ORM1—nervous system—attention deficit hyperactivity disorder	0.00613	0.00721	CbGeAlD
Erlotinib—ORM1—central nervous system—attention deficit hyperactivity disorder	0.0059	0.00694	CbGeAlD
Erlotinib—SLCO2B1—nervous system—attention deficit hyperactivity disorder	0.00587	0.00691	CbGeAlD
Erlotinib—ABL1—nervous system—attention deficit hyperactivity disorder	0.00582	0.00685	CbGeAlD
Erlotinib—MAP2K5—brain—attention deficit hyperactivity disorder	0.00577	0.00679	CbGeAlD
Erlotinib—SLCO2B1—central nervous system—attention deficit hyperactivity disorder	0.00565	0.00665	CbGeAlD
Erlotinib—ABL1—central nervous system—attention deficit hyperactivity disorder	0.0056	0.00659	CbGeAlD
Erlotinib—SLCO2B1—cerebellum—attention deficit hyperactivity disorder	0.00552	0.0065	CbGeAlD
Erlotinib—ABL1—cerebellum—attention deficit hyperactivity disorder	0.00548	0.00644	CbGeAlD
Erlotinib—CYP1B1—nervous system—attention deficit hyperactivity disorder	0.00493	0.0058	CbGeAlD
Erlotinib—CYP1B1—central nervous system—attention deficit hyperactivity disorder	0.00475	0.00558	CbGeAlD
Erlotinib—CYP1B1—cerebellum—attention deficit hyperactivity disorder	0.00464	0.00546	CbGeAlD
Erlotinib—CYP2D6—forebrain—attention deficit hyperactivity disorder	0.00463	0.00545	CbGeAlD
Erlotinib—SLCO2B1—brain—attention deficit hyperactivity disorder	0.00449	0.00528	CbGeAlD
Erlotinib—ABCG2—midbrain—attention deficit hyperactivity disorder	0.00446	0.00525	CbGeAlD
Erlotinib—ABL1—brain—attention deficit hyperactivity disorder	0.00445	0.00523	CbGeAlD
Erlotinib—ALB—brain—attention deficit hyperactivity disorder	0.00411	0.00483	CbGeAlD
Erlotinib—CYP1B1—brain—attention deficit hyperactivity disorder	0.00377	0.00443	CbGeAlD
Erlotinib—CYP1A1—nervous system—attention deficit hyperactivity disorder	0.00348	0.0041	CbGeAlD
Erlotinib—ABCG2—cerebellum—attention deficit hyperactivity disorder	0.00345	0.00406	CbGeAlD
Erlotinib—CYP1A1—central nervous system—attention deficit hyperactivity disorder	0.00335	0.00395	CbGeAlD
Erlotinib—ABCB1—forebrain—attention deficit hyperactivity disorder	0.00333	0.00392	CbGeAlD
Erlotinib—CYP2C8—brain—attention deficit hyperactivity disorder	0.00289	0.00339	CbGeAlD
Erlotinib—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.00282	0.00332	CbGeAlD
Erlotinib—ABCG2—brain—attention deficit hyperactivity disorder	0.00281	0.0033	CbGeAlD
Erlotinib—CYP1A1—brain—attention deficit hyperactivity disorder	0.00266	0.00313	CbGeAlD
Erlotinib—CYP3A4—nervous system—attention deficit hyperactivity disorder	0.00256	0.00301	CbGeAlD
Erlotinib—CYP2D6—nervous system—attention deficit hyperactivity disorder	0.00252	0.00296	CbGeAlD
Erlotinib—CYP3A4—central nervous system—attention deficit hyperactivity disorder	0.00246	0.0029	CbGeAlD
Erlotinib—CYP2D6—central nervous system—attention deficit hyperactivity disorder	0.00242	0.00285	CbGeAlD
Erlotinib—CYP2D6—cerebellum—attention deficit hyperactivity disorder	0.00237	0.00279	CbGeAlD
Erlotinib—ABCB1—midbrain—attention deficit hyperactivity disorder	0.0022	0.00259	CbGeAlD
Erlotinib—CYP2D6—brain—attention deficit hyperactivity disorder	0.00192	0.00226	CbGeAlD
Erlotinib—ABCB1—nervous system—attention deficit hyperactivity disorder	0.00181	0.00213	CbGeAlD
Erlotinib—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00174	0.00205	CbGeAlD
Erlotinib—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.0017	0.002	CbGeAlD
Erlotinib—ABCB1—brain—attention deficit hyperactivity disorder	0.00138	0.00163	CbGeAlD
Erlotinib—ABL1—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00034	0.00226	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000339	0.00226	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000334	0.00222	CbGpPWpGaD
Erlotinib—EGFR—Androgen receptor signaling pathway—EP300—attention deficit hyperactivity disorder	0.000332	0.00221	CbGpPWpGaD
Erlotinib—ABL1—Immune System—STUB1—attention deficit hyperactivity disorder	0.000329	0.00219	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000325	0.00216	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CACNB2—attention deficit hyperactivity disorder	0.000324	0.00216	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000323	0.00215	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000322	0.00214	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000322	0.00214	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000318	0.00212	CbGpPWpGaD
Erlotinib—CYP1A2—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.000315	0.0021	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000314	0.00209	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00031	0.00206	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.000309	0.00206	CbGpPWpGaD
Erlotinib—CYP3A5—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000306	0.00204	CbGpPWpGaD
Erlotinib—CYP3A5—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000303	0.00202	CbGpPWpGaD
Erlotinib—CYP3A5—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000301	0.00201	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—CACNA1C—attention deficit hyperactivity disorder	0.000297	0.00198	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000292	0.00195	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000291	0.00194	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MB21D1—attention deficit hyperactivity disorder	0.00029	0.00193	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000289	0.00192	CbGpPWpGaD
Erlotinib—CYP1A1—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000287	0.00191	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000285	0.0019	CbGpPWpGaD
Erlotinib—CYP1A1—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000285	0.0019	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.000285	0.0019	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000283	0.00189	CbGpPWpGaD
Erlotinib—EGFR—Immune System—STUB1—attention deficit hyperactivity disorder	0.000281	0.00187	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000281	0.00187	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00028	0.00186	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000279	0.00186	CbGpPWpGaD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—EP300—attention deficit hyperactivity disorder	0.000277	0.00184	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.000271	0.00181	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.000271	0.0018	CbGpPWpGaD
Erlotinib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.000266	0.00177	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000265	0.00177	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000265	0.00176	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.000264	0.00176	CbGpPWpGaD
Erlotinib—CYP2C8—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000263	0.00175	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000261	0.00174	CbGpPWpGaD
Erlotinib—CYP2C8—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000261	0.00174	CbGpPWpGaD
Erlotinib—EGFR—Disease—STUB1—attention deficit hyperactivity disorder	0.00026	0.00173	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.000259	0.00173	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000254	0.0017	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000253	0.00169	CbGpPWpGaD
Erlotinib—ABL1—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000249	0.00166	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000249	0.00166	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000246	0.00164	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000243	0.00162	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—EP300—attention deficit hyperactivity disorder	0.000235	0.00157	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.000233	0.00155	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—EP300—attention deficit hyperactivity disorder	0.000231	0.00154	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000229	0.00152	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—EP300—attention deficit hyperactivity disorder	0.000227	0.00151	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.000227	0.00151	CbGpPWpGaD
Erlotinib—JAK3—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000225	0.0015	CbGpPWpGaD
Erlotinib—ALB—SLC-mediated transmembrane transport—SLC6A3—attention deficit hyperactivity disorder	0.000222	0.00148	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000217	0.00145	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000217	0.00145	CbGpPWpGaD
Erlotinib—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000216	0.00144	CbGpPWpGaD
Erlotinib—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000214	0.00143	CbGpPWpGaD
Erlotinib—EGFR—Immune System—POLR3A—attention deficit hyperactivity disorder	0.000213	0.00142	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000213	0.00142	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000212	0.00141	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.000211	0.0014	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000206	0.00137	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000205	0.00136	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000203	0.00135	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000198	0.00132	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000197	0.00131	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000192	0.00128	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000191	0.00127	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000189	0.00126	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000188	0.00125	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000185	0.00123	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000184	0.00123	CbGpPWpGaD
Erlotinib—ABCG2—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000183	0.00122	CbGpPWpGaD
Erlotinib—CYP1A2—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000183	0.00122	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.000182	0.00121	CbGpPWpGaD
Erlotinib—CYP1A2—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.000182	0.00121	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00018	0.0012	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.00018	0.0012	CbGpPWpGaD
Erlotinib—CYP1A1—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.000177	0.00118	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000174	0.00116	CbGpPWpGaD
Erlotinib—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.000173	0.00115	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000173	0.00115	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000173	0.00115	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000161	0.00107	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00016	0.00107	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.000157	0.00105	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.000156	0.00104	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000156	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.000153	0.00102	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000153	0.00102	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000151	0.00101	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00015	0.001	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000146	0.000972	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.000142	0.000946	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000142	0.000945	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000142	0.000945	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000141	0.000942	CbGpPWpGaD
Erlotinib—CYP3A4—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.000141	0.00094	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000141	0.000937	CbGpPWpGaD
Erlotinib—CYP3A4—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00014	0.000933	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00014	0.00093	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.000139	0.000929	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000139	0.000925	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.000137	0.000914	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000132	0.000882	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000132	0.000882	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00013	0.000867	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00013	0.000865	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000128	0.000851	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000125	0.000833	CbGpPWpGaD
Erlotinib—EGFR—Disease—SNAP25—attention deficit hyperactivity disorder	0.000123	0.00082	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EP300—attention deficit hyperactivity disorder	0.000121	0.000808	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000121	0.000806	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000121	0.000805	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00012	0.000802	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00012	0.000802	CbGpPWpGaD
Erlotinib—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.000119	0.000795	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000118	0.000789	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000118	0.000787	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000113	0.000756	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000113	0.000753	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00011	0.000734	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000108	0.000721	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000108	0.000719	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000108	0.000717	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000106	0.000707	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000106	0.000705	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000101	0.000671	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EP300—attention deficit hyperactivity disorder	9.91e-05	0.00066	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	9.9e-05	0.00066	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EP300—attention deficit hyperactivity disorder	9.86e-05	0.000657	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.85e-05	0.000657	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—EP300—attention deficit hyperactivity disorder	9.67e-05	0.000644	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SNAP25—attention deficit hyperactivity disorder	9.62e-05	0.000641	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	9.43e-05	0.000628	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	9.27e-05	0.000618	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	9.16e-05	0.00061	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	9.09e-05	0.000606	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	8.95e-05	0.000596	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	8.89e-05	0.000592	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EP300—attention deficit hyperactivity disorder	8.71e-05	0.00058	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TPH2—attention deficit hyperactivity disorder	8.63e-05	0.000575	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.63e-05	0.000575	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	8.62e-05	0.000574	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—COMT—attention deficit hyperactivity disorder	8.6e-05	0.000573	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	8.54e-05	0.000569	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.49e-05	0.000566	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—DPYD—attention deficit hyperactivity disorder	8.49e-05	0.000565	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—EP300—attention deficit hyperactivity disorder	8.42e-05	0.000561	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	8.35e-05	0.000556	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	8.21e-05	0.000547	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TPH2—attention deficit hyperactivity disorder	8.15e-05	0.000543	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CACNB2—attention deficit hyperactivity disorder	8.15e-05	0.000543	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	8.1e-05	0.00054	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—COMT—attention deficit hyperactivity disorder	8.02e-05	0.000534	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—DPYD—attention deficit hyperactivity disorder	8.02e-05	0.000534	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MAOA—attention deficit hyperactivity disorder	7.96e-05	0.00053	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.89e-05	0.000526	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	7.72e-05	0.000514	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	7.55e-05	0.000503	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ADRA2C—attention deficit hyperactivity disorder	7.53e-05	0.000502	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TPH2—attention deficit hyperactivity disorder	7.47e-05	0.000498	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.47e-05	0.000498	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	7.45e-05	0.000497	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—EP300—attention deficit hyperactivity disorder	7.44e-05	0.000496	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TPH2—attention deficit hyperactivity disorder	7.43e-05	0.000495	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CACNB2—attention deficit hyperactivity disorder	7.43e-05	0.000495	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—DPYD—attention deficit hyperactivity disorder	7.35e-05	0.00049	CbGpPWpGaD
Erlotinib—ALB—Metabolism—DPYD—attention deficit hyperactivity disorder	7.31e-05	0.000487	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—COMT—attention deficit hyperactivity disorder	7.29e-05	0.000486	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MAOA—attention deficit hyperactivity disorder	7.24e-05	0.000483	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.9e-05	0.000459	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.83e-05	0.000455	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CACNA1C—attention deficit hyperactivity disorder	6.79e-05	0.000453	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.56e-05	0.000437	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SNAP25—attention deficit hyperactivity disorder	6.51e-05	0.000434	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	6.51e-05	0.000434	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.51e-05	0.000434	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.4e-05	0.000427	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	6.4e-05	0.000427	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	6.2e-05	0.000413	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	6.13e-05	0.000409	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	6.13e-05	0.000409	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	6.03e-05	0.000402	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.97e-05	0.000398	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.95e-05	0.000397	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.94e-05	0.000396	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADRA2C—attention deficit hyperactivity disorder	5.81e-05	0.000387	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.69e-05	0.000379	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ADRA2A—attention deficit hyperactivity disorder	5.65e-05	0.000377	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	5.61e-05	0.000374	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	5.29e-05	0.000352	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—COMT—attention deficit hyperactivity disorder	5.23e-05	0.000348	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.22e-05	0.000348	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	5.2e-05	0.000347	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TPH2—attention deficit hyperactivity disorder	5.2e-05	0.000346	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CACNB2—attention deficit hyperactivity disorder	5.2e-05	0.000346	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MAOA—attention deficit hyperactivity disorder	5.19e-05	0.000346	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—DPYD—attention deficit hyperactivity disorder	5.11e-05	0.000341	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EP300—attention deficit hyperactivity disorder	5.07e-05	0.000338	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.95e-05	0.00033	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—COMT—attention deficit hyperactivity disorder	4.94e-05	0.000329	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.9e-05	0.000327	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MAOA—attention deficit hyperactivity disorder	4.9e-05	0.000327	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—EP300—attention deficit hyperactivity disorder	4.76e-05	0.000317	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.75e-05	0.000317	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CACNA1C—attention deficit hyperactivity disorder	4.75e-05	0.000317	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	4.67e-05	0.000311	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—COMT—attention deficit hyperactivity disorder	4.53e-05	0.000302	CbGpPWpGaD
Erlotinib—ALB—Metabolism—COMT—attention deficit hyperactivity disorder	4.5e-05	0.0003	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MAOA—attention deficit hyperactivity disorder	4.49e-05	0.000299	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MAOA—attention deficit hyperactivity disorder	4.47e-05	0.000298	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.36e-05	0.00029	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	4.33e-05	0.000289	CbGpPWpGaD
Erlotinib—EGFR—Immune System—EP300—attention deficit hyperactivity disorder	4.33e-05	0.000289	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SNAP25—attention deficit hyperactivity disorder	4.15e-05	0.000277	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TPH2—attention deficit hyperactivity disorder	4.01e-05	0.000267	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.01e-05	0.000267	CbGpPWpGaD
Erlotinib—EGFR—Disease—EP300—attention deficit hyperactivity disorder	4e-05	0.000267	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.95e-05	0.000263	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—DPYD—attention deficit hyperactivity disorder	3.95e-05	0.000263	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	3.94e-05	0.000263	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	3.92e-05	0.000261	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	3.72e-05	0.000248	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	3.69e-05	0.000246	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—EP300—attention deficit hyperactivity disorder	3.69e-05	0.000246	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.67e-05	0.000244	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—EP300—attention deficit hyperactivity disorder	3.44e-05	0.000229	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.21e-05	0.000214	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—COMT—attention deficit hyperactivity disorder	3.15e-05	0.00021	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—EP300—attention deficit hyperactivity disorder	3.13e-05	0.000208	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MAOA—attention deficit hyperactivity disorder	3.13e-05	0.000208	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.05e-05	0.000203	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	3.03e-05	0.000202	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EP300—attention deficit hyperactivity disorder	2.8e-05	0.000187	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—COMT—attention deficit hyperactivity disorder	2.43e-05	0.000162	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MAOA—attention deficit hyperactivity disorder	2.41e-05	0.000161	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—EP300—attention deficit hyperactivity disorder	2.24e-05	0.000149	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—EP300—attention deficit hyperactivity disorder	2.12e-05	0.000141	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—EP300—attention deficit hyperactivity disorder	1.94e-05	0.000129	CbGpPWpGaD
Erlotinib—ALB—Metabolism—EP300—attention deficit hyperactivity disorder	1.93e-05	0.000129	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	1.69e-05	0.000113	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	1.59e-05	0.000106	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—EP300—attention deficit hyperactivity disorder	1.35e-05	8.99e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—EP300—attention deficit hyperactivity disorder	1.04e-05	6.94e-05	CbGpPWpGaD
